Esmolol: Nursing Drug Guide, Bradycardia & IV Titration

Esmolol is marketed as Brevibloc (esmolol hydrochloride injection) and as generic esmolol hydrochloride in premixed bags or pharmacy-prepared infusions. Verify the MAR lists both generic and brand names—pump programming errors often trace to concentration or mcg/kg/min assumptions.

Do not confuse Brevibloc bags with other IV vasoactive drips in the medication room; beta-blocker bags may look similar to other clear solutions at a glance.

Per Brevibloc and generic esmolol prescribing information, esmolol is used for short-term control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter, and for treatment of perioperative tachycardia and hypertension when short-duration beta blockade is needed.

↔On a small screen, swipe or scroll sideways to see the full table.

Esmolol is a cardioselective beta-1 adrenergic blocker. It decreases heart rate and myocardial contractility, lowering cardiac output and blood pressure. Its ester structure allows rapid hydrolysis by red-cell esterases, giving an elimination half-life of approximately 9 minutes—onset and offset follow infusion changes within minutes.

Unlike longer-acting agents such as digoxin, esmolol does not rely on renal clearance for termination—still monitor perfusion because hemodynamic effects are immediate during titration.

Individualize all rates to patient weight in mcg/kg/min. Double-check pump programming and independent weight verification before loading doses or titration.

Supraventricular tachycardia (label)

Perioperative hypertension / tachycardia (label)

↔On a small screen, swipe or scroll sideways to see the full table.

Renal / hepatic impairment: No dose adjustment required for standard maintenance per labeling—metabolism is via ester hydrolysis. Still monitor hemodynamics closely in organ dysfunction.

Transition to oral beta-blocker: Reduce esmolol infusion rate by 50% thirty minutes after the first dose of the oral alternative; stop esmolol after the second oral dose if the patient remains stable for one hour.

Pretreatment checks

• Perform medication reconciliation—confirm no IV verapamil ordered or running; verify oral beta-blocker transition plan
• Confirm cardiac telemetry or continuous monitoring available for active titration
• Assess baseline heart rate, blood pressure, lung sounds, and perfusion; review history of heart failure
• Verify patient weight, bag concentration, and pump rate in mcg/kg/min with independent double-check
• Screen for reactive airway disease—beta blockers may worsen bronchospasm in susceptible patients with asthma

Contraindications

• Severe sinus bradycardia; heart block greater than first degree; sick sinus syndrome without pacemaker
• Decompensated heart failure; cardiogenic shock
• Pulmonary hypertension
• IV verapamil in close proximity—may be fatal
• Known hypersensitivity to esmolol or formulation components

Warnings (labeling)

• Bradycardia and hypotension: Most common adverse effects (>10%) include symptomatic and asymptomatic hypotension—decrease rate or hold when thresholds crossed
• Cardiac failure: Negative inotropy can worsen decompensation—monitor for pulmonary edema and poor perfusion
• Reactive airways: Use caution in bronchospastic disease despite beta-1 selectivity
• Diabetes: May mask tachycardia from hypoglycemia—teach patients with type 2 diabetes to monitor glucose closely
• Dilution errors: Wrong concentration or mcg/kg/min programming causes rapid over- or under-dosing

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Intravenous bolus and continuous infusion. Available as premixed 10 mg/mL (2500 mg/250 mL) or 10 mg/mL (100 mg/10 mL) formulations per labeling; institutions may dilute further per pharmacy protocol—never assume concentration without reading the bag label.

• Use infusion pump with weight-based mcg/kg/min programming when ordered
• Independent double-check weight, concentration, rate, and line assignment before starting or changing
• Administer loading doses over the ordered duration (1 minute or 30 seconds per indication)—do not push undiluted bolus faster than prescribed
• Do not co-infuse incompatible agents (sodium bicarbonate 5%, furosemide) in the same line
• Label line clearly as esmolol; communicate dedicated-line status at handoff

• Decrease in ventricular rate during rapid heart rate within minutes of effective dosing
• Heart rate and blood pressure within prescriber-defined targets without symptomatic hypotension
• Improved perfusion symptoms (less palpitations or chest pressure) when tachycardia was driving symptoms
• Smooth transition orders to oral beta-blocker before planned esmolol discontinuation

Escalate immediately for perfusion failure, high-grade block, or suspected drug interaction.

• Heart rate below prescriber minimum or symptomatic bradycardia with dizziness, syncope, or altered mental status—decrease or hold infusion
• Systolic hypotension with poor perfusion, oliguria, or cool clammy extremities
• New or worsening chest pain, pulmonary edema, or crackles suggesting cardiac failure
• Second- or third-degree heart block on monitor—hold and notify immediately
• IV verapamil ordered or discovered on MAR while esmolol is infusing—stop and clarify before either continues

↔On a small screen, swipe or scroll sideways to see the full table.

Overdose manifests as excessive beta blockade—profound bradycardia, hypotension, and cardiac failure.

Management (labeling)

• Stop esmolol infusion immediately
• Bradycardia: atropine per prescriber and protocol
• Cardiac failure: glucagon, isoproterenol, dopamine, or dobutamine per prescriber orders
• Hypotension: IV fluids and vasopressors as indicated

Antidote: No single reversal agent—effects wane within minutes after stop due to short half-life, but support hemodynamics until stable.

• Brevibloc vs other IV drips—verify drug name, concentration, and line at pump programming; do not confuse with nitroglycerin, nicardipine, or amiodarone bags
• mcg/kg/min vs mg/hour—independent double-check every titration; weight entry errors cause tenfold dosing mistakes
• Premixed vs pharmacy-diluted bags—read label concentration before programming; never assume standard dilution
• Esmolol vs metoprolol orders—IV esmolol and oral metoprolol may appear together during transition; clarify which is active and transition steps
• Verapamil name similarity—both are rate-control agents; IV verapamil near esmolol is contraindicated—highlight on MAR review

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Continuous ECG/telemetry during active titration and until stable on maintenance rate
• Heart rate and blood pressure every 1–5 minutes during loading and titration per protocol
• Perfusion: mental status, urine output, skin temperature, and lung sounds
• Blood glucose in patients with diabetes when symptomatic
• Signs of heart failure or bronchospasm throughout therapy

Document

• Indication, weight used for calculation, starting rate, and prescriber heart rate/blood pressure targets
• Each titration with paired vitals and nurse initials on double-check
• Bag concentration, lot, and line label verification
• Oral beta-blocker transition doses and esmolol rate reductions per protocol

• This IV medicine slows your heart rate quickly—the team will check your pulse and blood pressure often and adjust the drip
• Report dizziness, faintness, shortness of breath, chest discomfort, or feeling like your heart is beating too slowly
• When switching to oral heart-rate medicine, take pills exactly as directed so your heart rate does not jump up when the IV stops
• If you have diabetes, monitor blood sugar as instructed because this medicine can hide low-sugar warning signs
• Ask before getting out of bed—low blood pressure can cause falls

Do not start or continue and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for esmolol infusion safety using a tabbed case (MAR, labs, vitals, and nursing notes), plus priority action, select-all-that-apply cues, trend interpretation, matrix urgency, and documentation cloze items tied to postoperative SVT, bradycardia, hypotension, and verapamil interaction risk.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.